🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If you are planning to travel or go on #Holiday, and are affected by #Lymphoma, there may be some some additional things to consider. Read top tips from our community, from planning to packing 👉 lymphoma-action.org.uk/top-tips-travel Share your experiences in the comments 💜.

A new Science Immunology Review examines the multifaceted ways in which T follicular helper cells modulate immune responses during infection, allergy, and autoimmune diseases. scim.ag/4jMG3bO

Selecting CAR-T vs BsAbs in r/r follicular #lymphoma 🧐 Meet the professor Gloria Iacoboni reviewing T-cell redirecting therapies in DLBCL and FL! 👏 #ICML2025 #18ICML International Conference on Malignant Lymphoma GELTAMO

CONGRESS | #18ICML | PRESENTATION Juan Pablo Alderuccio Juan P. Alderuccio Sylvester Comprehensive Cancer Center presents the initial results from LOTIS-7, evaluating loncastuximab tesirine plus glofitamab in patients with R/R #DLBCL. ORR across all dose levels 93.3%, with a CR rate of 86.7%. Most

Lotis-7: loncaT with glofit RR DLBCL Small nos and early data but VERY high response rates with well over 80% CMR rate. One to watch. #18ICML #ICML25 #lymsm

CONGRESS | #18ICML | PRESENTATION Lijia Chen presents updated results from the phase II JACKPOT26 trial of golidocitinib as a maintenance therapy for patients with PTCL who achieved tumor response after 1L systemic therapy (N = 48). Golidocitinib showed promising efficacy in

Waleed Alduaij at #icmlugano last week presented this well conducted retrospective study from British Columbia on double hit lymphoma, suggesting a large benefit from DA EPOCHR vs RCHOP. But the PFS separation is very early, mostly <3 months...

Why does cytarabine hit the brain so hard? 🧠It causes DSBs, especially in Purkinje cells! Meanwhile, Gemcitabine plays much nicer! Check out our paper in Nature today! Huge thanks to my mentor André Nussenzweig andre nussenzweig lab and all my amazing colleagues! nature.com/articles/s4158…

Just out ! 🙌 by Claudel et al. RELEVANCE trial / FL Both ctDNA and PET+ at EOI are associated with shorter PFS. Combined ctDNA+PET is associated with POD24+ (NPV>90%, PPV ctDNA 58%, PPV PET 45%, PPV ctDNA+PET 86%). Lysa Lymphoma #lymsm ashpublications.org/blood/article-…

Association of Epstein-Barr virus genomic alterations with human pathologies | Blood | American Society of Hematology ashpublications.org/blood/article/…

Big thanks to a great team behind this novel & ambitious study Jessica Okosun Kate Cwynarski Graham McIlroy Nicolas Martinez 🇨🇴🇨🇴 #jeffsmith #bethphilips et al CRCTU Haematology Team Birmingham Cancer Research UK Clinical Trials Unit #TAPnetwork Accelerating Clinical Trials Cure Leukaemia Blood Cancer UK Research

Cancer chemotherapy does a number (as in mutations) to blood cells 2 new reports using single-cell sequencing show the deleterious effects of these drugs, yet another reason for better therapeutic approaches nature.com/articles/s4158… nature.com/articles/s4158… nature.com/articles/s4158…

Our spatial FFPE-ATAC-seq is now published in Nature Communications! With extensive optimizations, it performs well across diverse tissues, unlocking the vast FFPE archive for spatial epigenomics. Big congrats to Pengfei Guo Pengfei_Guo, Yufan Chen, and the team! nature.com/articles/s4146…

It’s back and it’s online. The fantastic #lymphomaManagement course. With much thanks to LymphomaAction for their support as always. Do sign up to learn about state of the art management of this fascinating disease from international experts. #lymsm

Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study | Blood Cancer Journal nature.com/articles/s4140…

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Fresh from #ICML2025 💜 Prof Jessica Okosun outlines key #FollicularLymphoma findings: - Tafasitamab + R2 gets FDA approval - ELARA confirms CAR T long-term impact - Bispecific antibodies advance globally Full report on our scientific learnings coming soon!

Online Now: Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention dlvr.it/TLjZ7t

Magrolimab, an anti-CD47 antibody, combined with obinutuzumab and venetoclax, is safe and induces durable responses in relapsed/refractory indolent B-cell lymphomas. Rahul Lakhotia Mark Roschewski Christopher Melani buff.ly/xXzEhOI

Catch up on the latest developments in lymphoma and CLL with our coverage from the #18ICML Congress, June 17–21, 2025, Lugano, CH, and online. Aggressive B-cell NHL: loom.ly/Pc0ysis CLL/SLL: loom.ly/24wdL6A Indolent and mantle cell NHL: loom.ly/Rqi0ydI